Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer

Author(s): Yuao Deng, Longyang Liu, Weifeng Feng, Zhongqiu Lin, Yingxia Ning* and Xin Luo*

Volume 16, Issue 4, 2021

Published on: 06 July, 2021

Page: [533 - 539] Pages: 7

DOI: 10.2174/1574891X16666210706153740

Price: $65

Abstract

Background: The prognosis of Epithelial Ovarian Cancer (EOC) is poor, but the prognostic biomarkers are neither sensitive nor specific. Therefore, it is very important to search novel prognostic biomarkers for EOC.

Objectives: The present study aimed to investigate Myosin Light Chain 9(MYL9) expression in Epithelial Ovarian Cancer (EOC) tissues (including paraffin-embedded and fresh tissue samples) and its relationship with clinicopathological characteristics, as well as its potential prognostic value in patients with EOC.

Methods: Between March 2009 and December 2018, all of 184 paraffin-embedded cancer tissues from patients with EOC and 41 paratumor tissues, pathologically confirmed at the Memorial Hospital of Sun Yat-sen University and Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, were collected for the present study and were assessed for MYL9 protein expression patterns using Immunohistochemistry (IHC). Furthermore, from August 2013 to November 2019, 16 fresh EOC tissues and their paired paratumor tissues, pathologically confirmed at the Integrated Hospital of Traditional Chinese Medicine, Southern Medical University were analyzed using Reverse-Transcription Quantitative PCR (RT-qPCR) to detect MYL9 mRNA expression levels.

Results: The results showed that MYL9 expression was higher in cancer tissues compared with that in paratumor tissues, and MYL9 overexpression was associated with shorter Recurrence Free Survival (RFS) and Overall Survival (OS) of EOC patients. Furthermore, multivariate Cox model analysis indicated that MYL9 overexpression was an independent poor survival prediction in patients with EOC.

Conclusion: MYL9 is upregulated in EOC and may serve as a useful patent of prognostic biomarker in EOC, and it may demonstrate an important value for the clinical treatment and supervision of patients with EOC.

Keywords: Expression of MYL9, clinical prognosis, Epithelial Ovarian Cancer, biomarkers, linicopathological parameters, paratumor tissues.

« Previous Next »
[1]
Mittica G, Ghisoni E, Giannone G, et al. PARP inhibitors in ovarian cancer. Recent Pat Anticancer Drug Discov 2018; 13(4): 392-410.
[http://dx.doi.org/10.2174/1574892813666180305165256] [PMID: 29512470]
[2]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115-32.
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[3]
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69(4): 280-304.
[http://dx.doi.org/10.3322/caac.21559] [PMID: 31099893]
[4]
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68(4): 284-96.
[http://dx.doi.org/10.3322/caac.21456] [PMID: 29809280]
[5]
Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68(4): 297-316.
[http://dx.doi.org/10.3322/caac.21446] [PMID: 29846940]
[6]
Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep 2018; 8(1): 12394.
[http://dx.doi.org/10.1038/s41598-018-30261-8] [PMID: 30120290]
[7]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[8]
Shen J, Yu S, Sun X, Yin M, Fei J, Zhou J. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: Evidence from bioinformatic analysis. J Ovarian Res 2019; 12(1): 110.
[http://dx.doi.org/10.1186/s13048-019-0578-1] [PMID: 31729978]
[9]
Yang WL, Lu Z, Guo J, et al. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer 2020; 126(4): 725-36.
[http://dx.doi.org/10.1002/cncr.32582] [PMID: 31714597]
[10]
Perez-Juarez CE, Arechavaleta-Velasco F, Zeferino-Toquero M, Alvarez-Arellano L, Estrada-Moscoso I, Diaz-Cueto L. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in Ovarian Clear Cell Carcinoma (OCCC) cell line: A potential biomarker for therapy response to signaling pathway inhibitors. Med Oncol 2019; 37(1): 4.
[http://dx.doi.org/10.1007/s12032-019-1326-5] [PMID: 31713081]
[11]
Liu L, Zeng Z, Yi J, et al. Expression and clinical significance of Transcription Factor 4 (TCF4) in epithelial ovarian cancer. Cancer Biomark 2019; 24(2): 213-21.
[http://dx.doi.org/10.3233/CBM-181849] [PMID: 30614797]
[12]
Liu L, Yi J, Deng X, et al. MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer. Oncol Lett 2019; 18(2): 1049-56.
[http://dx.doi.org/10.3892/ol.2019.10406] [PMID: 31423165]
[13]
Yao Y, Liu L, He W, et al. Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer. Cancer Biomark 2019; 26(4): 481-9.
[http://dx.doi.org/10.3233/CBM-190328] [PMID: 31658044]
[14]
Butte AJ, Szabo LA, Khatri P, Ling BX. Biomarkers for ovarian cancer. US20160291024, 2016.
[15]
O'shannessy DJ. Prognosis of serous ovarian cancer using biomarkers. US20190064172, 2019.
[16]
Wang JH, Zhang L, Huang ST, et al. Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma. PLoS One 2017; 12(4): e0175280.
[http://dx.doi.org/10.1371/journal.pone.0175280] [PMID: 28388691]
[17]
Ouderkirk JL, Krendel M. Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis. Cytoskeleton (Hoboken) 2014; 71(8): 447-63.
[http://dx.doi.org/10.1002/cm.21187] [PMID: 25087729]
[18]
Lu Y, Liu P, Wen W, et al. Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res 2010; 3(1): 8-27.
[PMID: 21139803]
[19]
Yan Z, Li J, Xiong Y, Xu W, Zheng G. Identification of candidate colon cancer biomarkers by applying a random forest approach on microarray data. Oncol Rep 2012; 28(3): 1036-42.
[http://dx.doi.org/10.3892/or.2012.1891] [PMID: 22752057]
[20]
Tan X, Chen M. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data. Tumour Biol 2014; 35(12): 12189-200.
[http://dx.doi.org/10.1007/s13277-014-2527-3] [PMID: 25179839]
[21]
Gu W, Ren JH, Zheng X, Hu XY, Hu MJ. Comprehensive analysis of expression profiles of long non-coding RNAs with associated ceRNA network involved in gastric cancer progression. Mol Med Rep 2019; 20(3): 2209-18.
[http://dx.doi.org/10.3892/mmr.2019.10478] [PMID: 31322220]
[22]
Huang YQ, Han ZD, Liang YX, et al. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer. Med Oncol 2014; 31(1): 820.
[http://dx.doi.org/10.1007/s12032-013-0820-4] [PMID: 24338276]
[23]
Kruthika BS, Sugur H, Nandaki K, Arimappamagan A, Paturu K, Santosh V. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma. J Clin Pathol 2019; 72(10): 677-81.
[http://dx.doi.org/10.1136/jclinpath-2019-205834] [PMID: 31270134]
[24]
Zhou H, Ma Y, Zhong D, Yang L. Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204. Biomed Pharmacother 2019; 112: 108633.
[http://dx.doi.org/10.1016/j.biopha.2019.108633] [PMID: 30784927]
[25]
Liu L, Ning Y, Yi J, et al. miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression. Biomed Pharmacother 2020; 125: 109865.
[http://dx.doi.org/10.1016/j.biopha.2020.109865] [PMID: 32058212]

Rights & Permissions Print Cite
Article Metrics
38
1
© 2024 Bentham Science Publishers | Privacy Policy